Ficlatuzumab

Drug Profile

Ficlatuzumab

Alternative Names: AV-299; SCH-900105

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; AVEO Pharmaceuticals; University of California at San Francisco
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Hepatocyte growth factor expression inhibitors; Hepatocyte growth factor inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia
  • No development reported Lymphoma; Multiple myeloma; Solid tumours
  • Discontinued Glioblastoma

Most Recent Events

  • 12 Sep 2016 AVEO terminates a phase I trial for Head and neck cancer prior to initiation of enrolment in USA (NCT02277184)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Monotherapy) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Monotherapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top